CDMO

Pharma

Enhertu, Akeso, Fujifilm-Regeneron—Fierce Pharma Asia

Enhertu delivered a positive readout in first-line breast cancer. Akeso's ivonescimab bagged another phase 3 win. Fujifilm signed a 10-year deal with Regeneron.

Angus Liu Apr 25, 2025 8:45am

Thermo Fisher adds $2B investment in US over next 4 years

Apr 24, 2025 2:50pm

Regeneron taps Fujifilm Diosynth for $3B production agreement

Apr 22, 2025 10:03am

Meribel makes CDMO debut after series of acquisitions in Europe

Apr 21, 2025 11:26am

Thera juggles multiple suitors, including $255M offer from CDMO

Apr 14, 2025 7:45am

CDMO PharmaLogic takes majority stake in radiopharma pro Agilera

Apr 9, 2025 3:00pm